Kristian Hillert Winther1, Steen Joop Bonnema2, Frederik Cold2, Birgit Debrabant2, Mads Nybo2, Søren Cold2, Laszlo Hegedüs2. 1. Department of Endocrinology and MetabolismOdense University Hospital, Kloevervaenget 10, 6. Sal, DK-5000 Odense C, DenmarkDepartment of OncologyOdense University Hospital, Odense, DenmarkDepartment of EpidemiologyBiostatistics and Biodemography, University of Southern Denmark, Odense, DenmarkDepartment of Clinical Biochemistry and PharmacologyOdense University Hospital, Odense, Denmark kristian.winther@rsyd.dk. 2. Department of Endocrinology and MetabolismOdense University Hospital, Kloevervaenget 10, 6. Sal, DK-5000 Odense C, DenmarkDepartment of OncologyOdense University Hospital, Odense, DenmarkDepartment of EpidemiologyBiostatistics and Biodemography, University of Southern Denmark, Odense, DenmarkDepartment of Clinical Biochemistry and PharmacologyOdense University Hospital, Odense, Denmark.
Abstract
OBJECTIVE: Selenium is present in the active site of proteins important for thyroid hormone synthesis and metabolism. The objective of this study is to investigate the effect of selenium supplementation in different doses on thyroid function, under conditions of suboptimal dietary selenium intake. DESIGN: The Danish PREvention of Cancer by Intervention with SElenium pilot study (DK-PRECISE) is a randomized, double-blinded, placebo-controlled trial. A total of 491 males and females aged 60-74 years were randomized to 100 μg (n=124), 200 μg (n=122), or 300 μg (n=119) selenium-enriched yeast or matching yeast-based placebo tablets (n=126). A total of 361 participants, equally distributed across treatment groups, completed the 5-year intervention period. METHODS: Plasma samples were analyzed for selenium and serum samples for TSH, free triiodothyronine (FT3), and free thyroxine (FT4) at baseline, and after 6 months, and 5 years of supplementation. RESULTS:Plasma selenium concentrations increased significantly and dose-dependently in treatment groups receiving selenium (P<0.001). Serum TSH and FT4 concentrations decreased significantly and dose-dependently by 0.066 mIU/l (P=0.010) and 0.11 pmol/l (P=0.015), respectively, per 100 μg/day increase, with insignificant differences between 6 months and 5 years. No significant effects were found for FT3 and FT3:FT4 ratio. CONCLUSIONS: In euthyroid subjects, selenium supplementation minutely and dose-dependently affects thyroid function, when compared with placebo, by decreasing serum TSH and FT4 concentrations. Based on these findings, selenium supplementation is not warranted under conditions of marginal selenium deficiency. However, a role for selenium supplementation in the treatment of autoimmune thyroid diseases is still unresolved.
RCT Entities:
OBJECTIVE:Selenium is present in the active site of proteins important for thyroid hormone synthesis and metabolism. The objective of this study is to investigate the effect of selenium supplementation in different doses on thyroid function, under conditions of suboptimal dietary selenium intake. DESIGN: The Danish PREvention of Cancer by Intervention with SElenium pilot study (DK-PRECISE) is a randomized, double-blinded, placebo-controlled trial. A total of 491 males and females aged 60-74 years were randomized to 100 μg (n=124), 200 μg (n=122), or 300 μg (n=119) selenium-enriched yeast or matching yeast-based placebo tablets (n=126). A total of 361 participants, equally distributed across treatment groups, completed the 5-year intervention period. METHODS: Plasma samples were analyzed for selenium and serum samples for TSH, free triiodothyronine (FT3), and free thyroxine (FT4) at baseline, and after 6 months, and 5 years of supplementation. RESULTS: Plasma selenium concentrations increased significantly and dose-dependently in treatment groups receiving selenium (P<0.001). Serum TSH and FT4 concentrations decreased significantly and dose-dependently by 0.066 mIU/l (P=0.010) and 0.11 pmol/l (P=0.015), respectively, per 100 μg/day increase, with insignificant differences between 6 months and 5 years. No significant effects were found for FT3 and FT3:FT4 ratio. CONCLUSIONS: In euthyroid subjects, selenium supplementation minutely and dose-dependently affects thyroid function, when compared with placebo, by decreasing serum TSH and FT4 concentrations. Based on these findings, selenium supplementation is not warranted under conditions of marginal selenium deficiency. However, a role for selenium supplementation in the treatment of autoimmune thyroid diseases is still unresolved.
Authors: G Mantovani; A M Isidori; C Moretti; C Di Dato; E Greco; P Ciolli; M Bonomi; L Petrone; A Fumarola; G Campagna; G Vannucchi; S Di Sante; C Pozza; A Faggiano; A Lenzi; E Giannetta Journal: Endocrine Date: 2019-05-25 Impact factor: 3.633
Authors: Gustavo R G Andrade; Bartira Gorgulho; Paulo A Lotufo; Isabela M Bensenor; Dirce M Marchioni Journal: Nutrients Date: 2018-05-30 Impact factor: 5.717
Authors: Maria Fiore; Gea Oliveri Conti; Rosario Caltabiano; Antonino Buffone; Pietro Zuccarello; Livia Cormaci; Matteo Angelo Cannizzaro; Margherita Ferrante Journal: Int J Environ Res Public Health Date: 2019-04-02 Impact factor: 3.390